CN101198623B - 用于调控和检测wisp活性的方法和组合物 - Google Patents

用于调控和检测wisp活性的方法和组合物 Download PDF

Info

Publication number
CN101198623B
CN101198623B CN2006800215473A CN200680021547A CN101198623B CN 101198623 B CN101198623 B CN 101198623B CN 2006800215473 A CN2006800215473 A CN 2006800215473A CN 200680021547 A CN200680021547 A CN 200680021547A CN 101198623 B CN101198623 B CN 101198623B
Authority
CN
China
Prior art keywords
wisp
cell
antibody
polypeptide
nrk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800215473A
Other languages
English (en)
Chinese (zh)
Other versions
CN101198623A (zh
Inventor
卢克·德斯诺耶斯
埃伦·菲尔瓦罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN101198623A publication Critical patent/CN101198623A/zh
Application granted granted Critical
Publication of CN101198623B publication Critical patent/CN101198623B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2006800215473A 2005-04-14 2006-04-13 用于调控和检测wisp活性的方法和组合物 Active CN101198623B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/105,876 US7455834B2 (en) 2002-06-29 2005-04-14 Methods and compositions for modulating and detecting WISP activity
US11/105,876 2005-04-14
PCT/US2006/014008 WO2006113402A1 (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity

Publications (2)

Publication Number Publication Date
CN101198623A CN101198623A (zh) 2008-06-11
CN101198623B true CN101198623B (zh) 2013-06-12

Family

ID=36809580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800215473A Active CN101198623B (zh) 2005-04-14 2006-04-13 用于调控和检测wisp活性的方法和组合物

Country Status (16)

Country Link
US (2) US7455834B2 (enExample)
EP (1) EP1869086B1 (enExample)
JP (1) JP4979684B2 (enExample)
KR (1) KR101320261B1 (enExample)
CN (1) CN101198623B (enExample)
AU (1) AU2006236649B2 (enExample)
BR (1) BRPI0612184A8 (enExample)
CA (1) CA2604933C (enExample)
ES (1) ES2388993T3 (enExample)
IL (1) IL186095A (enExample)
MX (1) MX2007012798A (enExample)
NO (1) NO20075825L (enExample)
NZ (1) NZ561709A (enExample)
RU (1) RU2412201C2 (enExample)
WO (1) WO2006113402A1 (enExample)
ZA (1) ZA200708738B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
US20160279269A1 (en) * 2013-03-27 2016-09-29 Ge Healthcare As Method and reagent for preparing a diagnostic composition
US10272154B2 (en) 2014-04-15 2019-04-30 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
KR102011366B1 (ko) * 2016-11-17 2019-10-14 연세대학교 산학협력단 암 전이 억제제의 스크리닝 방법
CN112118857A (zh) * 2018-05-17 2020-12-22 株式会社橄榄生物科技 用于预防或治疗视网膜疾病的包含ccn5作为活性成分的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021998A1 (en) * 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
WO2004003158A2 (en) * 2002-06-29 2004-01-08 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2479498A1 (en) 1999-03-08 2001-07-26 Genentech, Inc. Compositions and methods for the treatment of tumor
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
WO2005025603A2 (en) 2003-09-11 2005-03-24 Genentech, Inc. Methods of using wisp antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021998A1 (en) * 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
WO2004003158A2 (en) * 2002-06-29 2004-01-08 Genentech, Inc. Methods and compositions for modulating and detecting wisp activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAXENA NEELA ET AL.differential expression of WISP-1 and WISP-2 genes in normal and transformed human breast cell lines.《MOLECULAR AND CELLULAR BIOCHMISTRY》.2001,第228卷(第1-2期),99-104. *

Also Published As

Publication number Publication date
AU2006236649A2 (en) 2008-07-24
KR20080003344A (ko) 2008-01-07
NZ561709A (en) 2009-12-24
JP2008537958A (ja) 2008-10-02
AU2006236649A1 (en) 2006-10-26
RU2412201C2 (ru) 2011-02-20
CA2604933A1 (en) 2006-10-26
AU2006236649B2 (en) 2012-03-29
US7732567B2 (en) 2010-06-08
WO2006113402A1 (en) 2006-10-26
MX2007012798A (es) 2007-11-20
HK1112470A1 (en) 2008-09-05
EP1869086A1 (en) 2007-12-26
CN101198623A (zh) 2008-06-11
US20060147453A1 (en) 2006-07-06
US7455834B2 (en) 2008-11-25
ES2388993T3 (es) 2012-10-22
RU2007142005A (ru) 2009-05-20
IL186095A0 (en) 2008-01-20
BRPI0612184A8 (pt) 2017-12-26
JP4979684B2 (ja) 2012-07-18
EP1869086B1 (en) 2012-07-18
KR101320261B1 (ko) 2013-10-22
IL186095A (en) 2012-10-31
CA2604933C (en) 2014-07-08
ZA200708738B (en) 2009-01-28
NO20075825L (no) 2008-01-11
BRPI0612184A2 (pt) 2011-12-20
US20090148448A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
CN101948541B (zh) 用于肿瘤诊断和治疗的组合物和方法
CN101437536A (zh) 抗肿瘤细胞抗原抗体治疗
CN101563105A (zh) 用于抑制smad4-缺陷癌症的组合物和方法
Vitale et al. Animal models of medullary thyroid cancer: state of the art and view to the future
US7732567B2 (en) Methods and compositions for modulating and detecting wisp activity
CN102225200A (zh) 用于调控tweak和fn14活性的方法和组合物
CN101600449A (zh) Wnt拮抗剂及其在wnt介导的病症的诊断和治疗中的用途
US7456262B2 (en) Methods and composition for modulating and detecting wisp activity
CN101175769A (zh) 用于调控血管完整性的方法和组合物
ES2349162T3 (es) Procedimientos y composiciones para modular y detectar la actividad de wisp.
US20060292150A1 (en) Methods of using wisp antagonists
HK1112470B (en) Methods and compositions for modulating and detecting wisp activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant